04 September 2018
A report published in July 2016 by visiongain predicts that the worldwide biological drugs market will be worth $248.2 billion in 2020. That revenue forecast and others appear in Biologics Market Trends and Forecasts 2016-2026: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn.
Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and markets.
Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. These effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. They are able to generate multi-billion dollar revenues, with biologics representing eight out of the top ten best-selling drugs in 2015.
“The emergence of biosimilars is set to disrupt this market - although they can be a positive or a negative influence, depending on how companies adapt to their presence. Patents on many leading biologics are due to expire during the forecast period of our report, and payers are eager to cut costs in the face of declining healthcare budgets. As such, this is a crucial period in the history of the global biologics market, one which will determine its long term future.”
Along with revenue prediction for the overall world market for biologics, Visiongain’s new investigation shows forecasts from 2016 to 2026 for 13 individual submarkets:
• Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
• Monoclonal antibodies (mAbs)
• Fusion proteins
• Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
In addition that work shows revenue forecasts for 18 leading products, including Lantus, Humalog, Avonex, Rebif, Humira, Remicade, Herceptin and Enbrel.
The analyses also show overall biologic revenue forecasts to 2026 for 11 national markets:
• United States
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).
That updated study examines the worldwide biological drugs industry and market, exploring news, data, progress, trends, companies, products, R&D and biosimilars. Companies the work studies include Amgen, Bayer, Eli Lilly, GSK, Johnson & Johnson, Merck & Co., Novartis, Novo Nordisk, Pfizer, Roche and Sanofi.
Biologics Market Trends and Forecasts 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. That portfolio contains studies on pharmaceuticals, biotechnology, diagnostics and medical devices.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.